NATURE . COM {
}
Title:
Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer | Oncogene
Description:
Epithelial–mesenchymal transition (EMT) is an initiating event in tumor cell invasion and metastasis. It has been shown to occur in resistance to a range of cancer therapies, including tamoxifen. MicroRNAs (miRNAs) have been associated with EMT as well as resistance to standard therapies. To investigate the role of miRNAs in the development of resistance to tamoxifen as well as accompanying EMT-like properties, we established a tamoxifen-resistant (TamR) model by continually exposing MCF-7 breast cancer cells to tamoxifen. In addition to the molecular changes known to be involved in acquired tamoxifen resistance, TamR cells displayed mesenchymal features and had increased invasiveness. Genome-wide miRNA microarray analysis revealed that miRNA-375 was among the top downregulated miRNAs in resistant cells. Re-expression of miR-375 was sufficient to sensitize TamR cells to tamoxifen and partly reversed EMT. A combination of mRNA profiling, bioinformatics analysis and experimental validation identified metadherin (MTDH) as a direct target of miR-375. Knockdown of MTDH partially phenocopied the effects of miR-375 on the sensitivity to tamoxifen and the reversal of EMT. We observed an inverse correlation between the expression of miR-375 and its target MTDH in primary breast cancer samples, implying the pathological relevance of targeting. Finally, tamoxifen-treated patients with higher expression of MTDH had a shorter disease-free survival and higher risk of relapse. As most cancer-related deaths occur because of resistance to standard therapies and metastasis, re-expression of miR-375 or targeting MTDH might serve as potential therapeutic approaches for the treatment of TamR breast cancer.
Website Age:
30 years and 10 months (reg. 1994-08-11).
Matching Content Categories {📚}
- Science
- Education
- Health & Fitness
Content Management System {📝}
What CMS is nature.com built with?
Custom-built
No common CMS systems were detected on Nature.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of nature.com audience?
🌆 Monumental Traffic: 20M - 50M visitors per month
Based on our best estimate, this website will receive around 42,194,993 visitors per month in the current month.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Nature.com Make Money? {💸}
Display Ads {🎯}
The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.
Ads are managed by yourbow.com. Particular relationships are as follows:
Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.comReseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.comHow Much Does Nature.com Make? {💰}
Display Ads {🎯}
$531,700 per month
Our calculations suggest that Nature.com earns between $354,480 and $974,820 monthly online from display advertisements.
Keywords {🔍}
cells, mirna, tamr, cancer, tamoxifen, mtdh, expression, cell, breast, resistance, article, figure, mcf, google, scholar, cas, mirnas, emt, invasion, data, patients, shown, results, properties, compared, epithelial, emtlike, mesenchymal, genes, luciferase, assay, target, lines, significantly, supplementary, reduced, nature, reexpression, ecadherin, effects, higher, potential, viability, usa, analysis, mrna, direct, targeting, survival, line,
Topics {✒️}
nature portfolio privacy policy nature 1978 nature advertising gov/index er/her2-positive breast cancer social media translational research sciences high erbb2/her2-expressing patients 0/ reprints mirna-overexpression vectors pcmv-mirs epithelial–mesenchymal transition epithelial-mesenchymal transition creative commons attribution-noncommercial pharmaceutical research kaplan–meier survival curves tight cell–cell junctions total dna content anti-e-cadherin antibody poor-prognosis breast cancer hrp-conjugated secondary antibodies tight cell–cell contacts cancer-related deaths occur cancer-relevant deaths arise received tamoxifen monotherapy hoffmann-la roche limited luciferase-based viability assay hormone receptor-positive patients e-cadherin predominantly localized normalize qrt–pcr data benjamini–hochberg adjusted p author correspondence large gene-targeting spectrum review article epithelial poorer disease-free survival differentially expressed micrornas research ec50 dose-response analysis qrt–pcr data validation shorter disease-free survival dose-response curves showed poorer relapse-free survival hek-293ft cell line downregulating e-cadherin expression anchorage-independent growth capacity therapeutic strategies potential therapeutic approaches qrt–pcr data show absolute log fold-change
Schema {🗺️}
WebPage:
mainEntity:
headline:Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer
description:Epithelialâmesenchymal transition (EMT) is an initiating event in tumor cell invasion and metastasis. It has been shown to occur in resistance to a range of cancer therapies, including tamoxifen. MicroRNAs (miRNAs) have been associated with EMT as well as resistance to standard therapies. To investigate the role of miRNAs in the development of resistance to tamoxifen as well as accompanying EMT-like properties, we established a tamoxifen-resistant (TamR) model by continually exposing MCF-7 breast cancer cells to tamoxifen. In addition to the molecular changes known to be involved in acquired tamoxifen resistance, TamR cells displayed mesenchymal features and had increased invasiveness. Genome-wide miRNA microarray analysis revealed that miRNA-375 was among the top downregulated miRNAs in resistant cells. Re-expression of miR-375 was sufficient to sensitize TamR cells to tamoxifen and partly reversed EMT. A combination of mRNA profiling, bioinformatics analysis and experimental validation identified metadherin (MTDH) as a direct target of miR-375. Knockdown of MTDH partially phenocopied the effects of miR-375 on the sensitivity to tamoxifen and the reversal of EMT. We observed an inverse correlation between the expression of miR-375 and its target MTDH in primary breast cancer samples, implying the pathological relevance of targeting. Finally, tamoxifen-treated patients with higher expression of MTDH had a shorter disease-free survival and higher risk of relapse. As most cancer-related deaths occur because of resistance to standard therapies and metastasis, re-expression of miR-375 or targeting MTDH might serve as potential therapeutic approaches for the treatment of TamR breast cancer.
datePublished:2012-04-16T00:00:00Z
dateModified:2012-04-16T00:00:00Z
pageStart:1173
pageEnd:1182
sameAs:https://doi.org/10.1038/onc.2012.128
keywords:
Breast cancer
Cancer therapeutic resistance
Epithelialâmesenchymal transition
miRNAs
microRNAs
tamoxifen resistance
epithelialâmesenchymal transition
breast cancer
metadherin
Medicine/Public Health
general
Internal Medicine
Cell Biology
Human Genetics
Oncology
Apoptosis
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig1_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig2_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig3_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig4_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig5_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig6_HTML.jpg
isPartOf:
name:Oncogene
issn:
1476-5594
0950-9232
volumeNumber:32
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:A Ward
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
type:Person
name:A Balwierz
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
type:Person
name:J D Zhang
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
type:Person
name:M Küblbeck
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
type:Person
name:Y Pawitan
affiliation:
name:Karolinska Institute
address:
name:Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
type:PostalAddress
type:Organization
type:Person
name:T Hielscher
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
type:Person
name:S Wiemann
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
type:Person
name:Ã Sahin
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:1
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer
description:Epithelialâmesenchymal transition (EMT) is an initiating event in tumor cell invasion and metastasis. It has been shown to occur in resistance to a range of cancer therapies, including tamoxifen. MicroRNAs (miRNAs) have been associated with EMT as well as resistance to standard therapies. To investigate the role of miRNAs in the development of resistance to tamoxifen as well as accompanying EMT-like properties, we established a tamoxifen-resistant (TamR) model by continually exposing MCF-7 breast cancer cells to tamoxifen. In addition to the molecular changes known to be involved in acquired tamoxifen resistance, TamR cells displayed mesenchymal features and had increased invasiveness. Genome-wide miRNA microarray analysis revealed that miRNA-375 was among the top downregulated miRNAs in resistant cells. Re-expression of miR-375 was sufficient to sensitize TamR cells to tamoxifen and partly reversed EMT. A combination of mRNA profiling, bioinformatics analysis and experimental validation identified metadherin (MTDH) as a direct target of miR-375. Knockdown of MTDH partially phenocopied the effects of miR-375 on the sensitivity to tamoxifen and the reversal of EMT. We observed an inverse correlation between the expression of miR-375 and its target MTDH in primary breast cancer samples, implying the pathological relevance of targeting. Finally, tamoxifen-treated patients with higher expression of MTDH had a shorter disease-free survival and higher risk of relapse. As most cancer-related deaths occur because of resistance to standard therapies and metastasis, re-expression of miR-375 or targeting MTDH might serve as potential therapeutic approaches for the treatment of TamR breast cancer.
datePublished:2012-04-16T00:00:00Z
dateModified:2012-04-16T00:00:00Z
pageStart:1173
pageEnd:1182
sameAs:https://doi.org/10.1038/onc.2012.128
keywords:
Breast cancer
Cancer therapeutic resistance
Epithelialâmesenchymal transition
miRNAs
microRNAs
tamoxifen resistance
epithelialâmesenchymal transition
breast cancer
metadherin
Medicine/Public Health
general
Internal Medicine
Cell Biology
Human Genetics
Oncology
Apoptosis
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig1_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig2_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig3_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig4_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig5_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_Article_BFonc2012128_Fig6_HTML.jpg
isPartOf:
name:Oncogene
issn:
1476-5594
0950-9232
volumeNumber:32
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:A Ward
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
type:Person
name:A Balwierz
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
type:Person
name:J D Zhang
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
type:Person
name:M Küblbeck
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
type:Person
name:Y Pawitan
affiliation:
name:Karolinska Institute
address:
name:Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
type:PostalAddress
type:Organization
type:Person
name:T Hielscher
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
type:Person
name:S Wiemann
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
type:Person
name:Ã Sahin
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:1
["Periodical","PublicationVolume"]:
name:Oncogene
issn:
1476-5594
0950-9232
volumeNumber:32
Organization:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
name:Karolinska Institute
address:
name:Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
type:PostalAddress
name:German Cancer Research Center (DKFZ)
address:
name:Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:A Ward
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
name:A Balwierz
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
name:J D Zhang
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
name:M Küblbeck
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
name:Y Pawitan
affiliation:
name:Karolinska Institute
address:
name:Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
type:PostalAddress
type:Organization
name:T Hielscher
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
name:S Wiemann
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
name:Ã Sahin
affiliation:
name:German Cancer Research Center (DKFZ)
address:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
type:PostalAddress
type:Organization
email:[email protected]
PostalAddress:
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
name:Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
name:Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
name:Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
External Links {🔗}(100)
- What's the total monthly financial gain of http://dtp.nci.nih.gov/index.html?
- What's https://doi.org/10.1038%2Fnrc2193's gross income?
- What's the income generated by http://scholar.google.com/scholar_lookup?&title=Modelling%20breast%20cancer%3A%20one%20size%20does%20not%20fit%20all&journal=Nat%20Rev%20Cancer&doi=10.1038%2Fnrc2193&volume=7&pages=659-672&publication_year=2007&author=Vargo-Gogola%2CT&author=Rosen%2CJM each month?
- Learn how profitable https://doi.org/10.1210%2Fedrv-11-4-578 is on a monthly basis
- What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Endocrine%20pharmacology%20of%20antiestrogens%20as%20antitumor%20agents&journal=Endocr%20Rev&doi=10.1210%2Fedrv-11-4-578&volume=11&pages=578-610&publication_year=1990&author=Jordan%2CVC&author=Murphy%2CCS?
- Find out how much https://link.springer.com/doi/10.1007/BF01806018 earns monthly
- Financial intake of http://scholar.google.com/scholar_lookup?&title=Antiestrogen%20action%20in%20breast%20cancer%20cells%3A%20modulation%20of%20proliferation%20and%20protein%20synthesis%2C%20and%20interaction%20with%20estrogen%20receptors%20and%20additional%20antiestrogen%20binding%20sites&journal=Breast%20Cancer%20Res%20Treat&doi=10.1007%2FBF01806018&volume=5&pages=231-543&publication_year=1985&author=Katzenellenbogen%2CBS&author=Miller%2CMA&author=Mullick%2CA&author=Sheen%2CYY
- How much revenue does https://doi.org/10.1677%2Ferc.1.00776 produce monthly?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Mechanisms%20of%20tamoxifen%20resistance&journal=Endocr%20Relat%20Cancer.&doi=10.1677%2Ferc.1.00776&volume=11&pages=643-658&publication_year=2004&author=Ring%2CA&author=Dowsett%2CM?
- What's https://doi.org/10.1016%2Fj.cell.2009.11.007's gross income?
- Earnings of http://scholar.google.com/scholar_lookup?&title=Epithelial-mesenchymal%20transitions%20in%20development%20and%20disease&journal=Cell&doi=10.1016%2Fj.cell.2009.11.007&volume=139&pages=871-890&publication_year=2009&author=Thiery%2CJP&author=Acloque%2CH&author=Huang%2CRY&author=Nieto%2CMA
- What is the earnings of https://doi.org/10.1038%2Fnrc2620?
- What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Transitions%20between%20epithelial%20and%20mesenchymal%20states%3A%20acquisition%20of%20malignant%20and%20stem%20cell%20traits&journal=Nat%20Rev%20Cancer&doi=10.1038%2Fnrc2620&volume=9&pages=265-273&publication_year=2009&author=Polyak%2CK&author=Weinberg%2CRA?
- Learn how profitable https://doi.org/10.1074%2Fjbc.M804612200 is on a monthly basis
- Income figures for http://scholar.google.com/scholar_lookup?&title=MicroRNA-221%2F222%20confers%20tamoxifen%20resistance%20in%20breast%20cancer%20by%20targeting%20p27Kip1&journal=J%20Biol%20Chem&doi=10.1074%2Fjbc.M804612200&volume=283&pages=29897-29903&publication_year=2008&author=Miller%2CTE&author=Ghoshal%2CK&author=Ramaswamy%2CB&author=Roy%2CS&author=Datta%2CJ&author=Shapiro%2CCL
- How much cash flow does https://doi.org/10.1038%2Fncb1722 have monthly?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=The%20miR-200%20family%20and%20miR-205%20regulate%20epithelial%20to%20mesenchymal%20transition%20by%20targeting%20ZEB1%20and%20SIP1&journal=Nat%20Cell%20Biol&doi=10.1038%2Fncb1722&volume=10&pages=593-601&publication_year=2008&author=Gregory%2CPA&author=Bert%2CAG&author=Paterson%2CEL&author=Barry%2CSC&author=Tsykin%2CA&author=Farshid%2CG generate?
- How much does https://doi.org/10.1158%2F1078-0432.CCR-0433-03 gross monthly?
- What's the profit of http://scholar.google.com/scholar_lookup?&title=Long-term%20exposure%20to%20tamoxifen%20induces%20hypersensitivity%20to%20estradiol&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-0433-03&volume=10&pages=1530-1534&publication_year=2004&author=Berstein%2CLM&author=Wang%2CJP&author=Zheng%2CH&author=Yue%2CW&author=Conaway%2CM&author=Santen%2CRJ?
- How much profit does https://doi.org/10.1093%2Fjnci%2Fdjh166 generate?
- Monthly income for http://scholar.google.com/scholar_lookup?&title=Mechanisms%20of%20tamoxifen%20resistance%3A%20increased%20estrogen%20receptor-HER2%2Fneu%20cross-talk%20in%20ER%2FHER2-positive%20breast%20cancer&journal=J%20Natl%20Cancer%20Inst&doi=10.1093%2Fjnci%2Fdjh166&volume=96&pages=926-935&publication_year=2004&author=Shou%2CJ&author=Massarweh%2CS&author=Osborne%2CCK&author=Wakeling%2CAE&author=Ali%2CS&author=Weiss%2CH
- What's the financial outcome of https://link.springer.com/doi/10.1007/s10549-005-9120-9?
- Learn how profitable http://scholar.google.com/scholar_lookup?&title=Elevated%20Src%20activity%20promotes%20cellular%20invasion%20and%20motility%20in%20tamoxifen%20resistant%20breast%20cancer%20cells&journal=Breast%20Cancer%20Res%20Treat&doi=10.1007%2Fs10549-005-9120-9&volume=97&pages=263-274&publication_year=2006&author=Hiscox%2CS&author=Morgan%2CL&author=Green%2CTP&author=Barrow%2CD&author=Gee%2CJ&author=Nicholson%2CRI is on a monthly basis
- How much profit does https://doi.org/10.1073%2Fpnas.160016897 make?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Down-regulation%20of%20p21WAF1%2FCIP1%20or%20p27Kip1%20abrogates%20antiestrogen-mediated%20cell%20cycle%20arrest%20in%20human%20breast%20cancer%20cells&journal=Proc%20Natl%20Acad%20Sci%20USA.&doi=10.1073%2Fpnas.160016897&volume=97&pages=9042-9046&publication_year=2000&author=Cariou%2CS&author=Donovan%2CJC&author=Flanagan%2CWM&author=Milic%2CA&author=Bhattacharya%2CN&author=Slingerland%2CJM?
- Check the income stats for https://doi.org/10.1038%2F273345a0
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=Role%20of%20cell%20shape%20in%20growth%20control&journal=Nature&doi=10.1038%2F273345a0&volume=273&pages=345-349&publication_year=1978&author=Folkman%2CJ&author=Moscona%2CA?
- Discover the revenue of https://doi.org/10.1158%2F0008-5472.CAN-10-1318
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=Epigenetically%20deregulated%20microRNA-375%20is%20involved%20in%20a%20positive%20feedback%20loop%20with%20estrogen%20receptor%20alpha%20in%20breast%20cancer%20cells&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-10-1318&volume=70&pages=9175-9184&publication_year=2010&author=de%20Souza%20Rocha%20Simonini%2CP&author=Breiling%2CA&author=Gupta%2CN&author=Malekpour%2CM&author=Youns%2CM&author=Omranipour%2CR?
- What are the total earnings of https://doi.org/10.1016%2Fj.febslet.2011.06.025?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Epigenetic%20regulation%20of%20microRNA-375%20and%20its%20role%20in%20melanoma%20development%20in%20humans&journal=FEBS%20Lett&doi=10.1016%2Fj.febslet.2011.06.025&volume=585&pages=2467-2476&publication_year=2011&author=Mazar%2CJ&author=DeBlasio%2CD&author=Govindarajan%2CSS&author=Zhang%2CS&author=Perera%2CRJ produce monthly?
- How much does https://link.springer.com/doi/10.1007/s10585-008-9170-6 pull in monthly?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Epithelial%20mesenchymal%20transition%20traits%20in%20human%20breast%20cancer%20cell%20lines&journal=Clin%20Exp%20Metastasis&doi=10.1007%2Fs10585-008-9170-6&volume=25&pages=629-642&publication_year=2008&author=Blick%2CT&author=Widodo%2CE&author=Hugo%2CH&author=Waltham%2CM&author=Lenburg%2CME&author=Neve%2CRM produce monthly?
- What's the monthly income of https://doi.org/10.1016%2Fj.ccr.2006.10.008?
- See how much http://scholar.google.com/scholar_lookup?&title=A%20collection%20of%20breast%20cancer%20cell%20lines%20for%20the%20study%20of%20functionally%20distinct%20cancer%20subtypes&journal=Cancer%20Cell&doi=10.1016%2Fj.ccr.2006.10.008&volume=10&pages=515-527&publication_year=2006&author=Neve%2CRM&author=Chin%2CK&author=Fridlyand%2CJ&author=Yeh%2CJ&author=Baehner%2CFL&author=Fevr%2CT makes per month
- What's the financial outcome of https://doi.org/10.1101%2Fgad.1640608?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=The%20miR-200%20family%20determines%20the%20epithelial%20phenotype%20of%20cancer%20cells%20by%20targeting%20the%20E-cadherin%20repressors%20ZEB1%20and%20ZEB2&journal=Genes%20Dev&doi=10.1101%2Fgad.1640608&volume=22&pages=894-907&publication_year=2008&author=Park%2CSM&author=Gaur%2CAB&author=Lengyel%2CE&author=Peter%2CME?
- How much does https://doi.org/10.1016%2Fj.ccr.2008.11.013 gross monthly?
- http://scholar.google.com/scholar_lookup?&title=MTDH%20activation%20by%208q22%20genomic%20gain%20promotes%20chemoresistance%20and%20metastasis%20of%20poor-prognosis%20breast%20cancer&journal=Cancer%20Cell&doi=10.1016%2Fj.ccr.2008.11.013&volume=15&pages=9-20&publication_year=2009&author=Hu%2CG&author=Chong%2CRA&author=Yang%2CQ&author=Wei%2CY&author=Blanco%2CMA&author=Li%2CF's total income per month
- What's the monthly money flow for https://doi.org/10.1038%2Fonc.2011.223?
- What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Tamoxifen%20downregulation%20of%20miR-451%20increases%2014-3-3zeta%20and%20promotes%20breast%20cancer%20cell%20survival%20and%20endocrine%20resistance&journal=Oncogene&doi=10.1038%2Fonc.2011.223&volume=31&pages=39-47&publication_year=2012&author=Bergamaschi%2CA&author=Katzenellenbogen%2CBS?
- https://doi.org/10.1111%2Fj.1349-7006.2009.01260.x's financial summary
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Involvement%20of%20Pin1%20induction%20in%20epithelial-mesenchymal%20transition%20of%20tamoxifen-resistant%20breast%20cancer%20cells&journal=Cancer%20Sci&doi=10.1111%2Fj.1349-7006.2009.01260.x&volume=100&pages=1834-1841&publication_year=2009&author=Kim%2CMR&author=Choi%2CHK&author=Cho%2CKB&author=Kim%2CHS&author=Kang%2CKW produce monthly?
- What's the monthly money flow for https://doi.org/10.1038%2Fsj.onc.1208429?
- Financial intake of http://scholar.google.com/scholar_lookup?&title=DeltaEF1%20is%20a%20transcriptional%20repressor%20of%20E-cadherin%20and%20regulates%20epithelial%20plasticity%20in%20breast%20cancer%20cells&journal=Oncogene&doi=10.1038%2Fsj.onc.1208429&volume=24&pages=2375-2385&publication_year=2005&author=Eger%2CA&author=Aigner%2CK&author=Sonderegger%2CS&author=Dampier%2CB&author=Oehler%2CS&author=Schreiber%2CM
- Get to know what's the income of https://doi.org/10.1002%2Fijc.21355
- What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Tamoxifen%20resistance%20in%20MCF7%20cells%20promotes%20EMT-like%20behaviour%20and%20involves%20modulation%20of%20beta-catenin%20phosphorylation&journal=Int%20J%20Cancer&doi=10.1002%2Fijc.21355&volume=118&pages=290-301&publication_year=2006&author=Hiscox%2CS&author=Jiang%2CWG&author=Obermeier%2CK&author=Taylor%2CK&author=Morgan%2CL&author=Burmi%2CR?
- Check the income stats for https://doi.org/10.1158%2F0008-5472.CAN-09-1298
- Financial intake of http://scholar.google.com/scholar_lookup?&title=Up-regulation%20of%20miR-200%20and%20let-7%20by%20natural%20agents%20leads%20to%20the%20reversal%20of%20epithelial-to-mesenchymal%20transition%20in%20gemcitabine-resistant%20pancreatic%20cancer%20cells&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-09-1298&volume=69&pages=6704-6712&publication_year=2009&author=Li%2CY&author=VandenBoom%2CTG&author=Kong%2CD&author=Wang%2CZ&author=Ali%2CS&author=Philip%2CPA
- Earnings of https://doi.org/10.1038%2Fonc.2011.263
- Learn how profitable http://scholar.google.com/scholar_lookup?&title=MiR-200b%20and%20miR-15b%20regulate%20chemotherapy-induced%20epithelial-mesenchymal%20transition%20in%20human%20tongue%20cancer%20cells%20by%20targeting%20BMI1&journal=Oncogene&doi=10.1038%2Fonc.2011.263&volume=31&pages=432-445&publication_year=2012&author=Sun%2CL&author=Yao%2CY&author=Liu%2CB&author=Lin%2CZ&author=Lin%2CL&author=Yang%2CM is on a monthly basis
- Get to know https://doi.org/10.1158%2F0008-5472.CAN-09-2777's earnings
- http://scholar.google.com/scholar_lookup?&title=MicroRNA-375%20is%20downregulated%20in%20gastric%20carcinomas%20and%20regulates%20cell%20survival%20by%20targeting%20PDK1%20and%2014-3-3zeta&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-09-2777&volume=70&pages=2339-2349&publication_year=2010&author=Tsukamoto%2CY&author=Nakada%2CC&author=Noguchi%2CT&author=Tanigawa%2CM&author=Nguyen%2CLT&author=Uchida%2CT's financial summary
- What's the financial gain of https://doi.org/10.1002%2Fhep.22256?
- Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=MicroRNA%20profiling%20in%20hepatocellular%20tumors%20is%20associated%20with%20clinical%20features%20and%20oncogene%2Ftumor%20suppressor%20gene%20mutations&journal=Hepatology&doi=10.1002%2Fhep.22256&volume=47&pages=1955-1963&publication_year=2008&author=Ladeiro%2CY&author=Couchy%2CG&author=Balabaud%2CC&author=Bioulac-Sage%2CP&author=Pelletier%2CL&author=Rebouissou%2CS
- How much revenue does https://doi.org/10.1136%2Fgutjnl-2011-300178 bring in?
- What's the monthly income of http://scholar.google.com/scholar_lookup?&title=MicroRNA-375%20inhibits%20tumour%20growth%20and%20metastasis%20in%20oesophageal%20squamous%20cell%20carcinoma%20through%20repressing%20insulin-like%20growth%20factor%201%20receptor&journal=Gut&doi=10.1136%2Fgutjnl-2011-300178&volume=61&pages=33-42&publication_year=2012&author=Kong%2CKL&author=Kwong%2CDL&author=Chan%2CTH&author=Law%2CSY&author=Chen%2CL&author=Li%2CY?
- How profitable is https://doi.org/10.1111%2Fj.1349-7006.2011.01919.x?
- What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=Metadherin%20enhances%20the%20invasiveness%20of%20breast%20cancer%20cells%20by%20inducing%20epithelial%20to%20mesenchymal%20transition&journal=Cancer%20Sci&doi=10.1111%2Fj.1349-7006.2011.01919.x&volume=102&pages=1151-1157&publication_year=2011&author=Li%2CX&author=Kong%2CX&author=Huo%2CQ&author=Guo%2CH&author=Yan%2CS&author=Yuan%2CC?
- What's the total monthly financial gain of https://doi.org/10.1038%2Fonc.2010.201?
- http://scholar.google.com/scholar_lookup?&title=miR-200bc%2F429%20cluster%20targets%20PLC%CE%B31%20and%20differentially%20regulates%20proliferation%20and%20EGF-driven%20invasion%20than%20miR-200a%2F141%20in%20breast%20cancer&journal=Oncogene&doi=10.1038%2Fonc.2010.201&volume=29&issue=30&pages=4297-4306&publication_year=2010&author=Uhlmann%2CS&author=Zhang%2CJ%20D&author=Schw%C3%A4ger%2CA&author=Mannsperger%2CH&author=Riazalhosseini%2CY&author=Burmester%2CS&author=Ward%2CA&author=Korf%2CU&author=Wiemann%2CS&author=Sahin%2C%C3%96's revenue stream
- How profitable is https://link.springer.com/doi/10.1186/1752-0509-3-1?
- Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Modeling%20ERBB%20receptor-regulated%20G1%2FS%20transition%20to%20find%20novel%20targets%20for%20de%20novo%20trastuzumab%20resistance&journal=BMC%20Syst%20Biol&doi=10.1186%2F1752-0509-3-1&volume=3&publication_year=2009&author=Sahin%2CO&author=Frohlich%2CH&author=Lobke%2CC&author=Korf%2CU&author=Burmester%2CS&author=Majety%2CM
- How much money does https://doi.org/10.1371%2Fjournal.pone.0016915 make?
- How much does http://scholar.google.com/scholar_lookup?&title=miRNA-mRNA%20integrated%20analysis%20reveals%20roles%20for%20miRNAs%20in%20primary%20breast%20tumors&journal=PLoS%20One&doi=10.1371%2Fjournal.pone.0016915&volume=6&publication_year=2011&author=Enerly%2CE&author=Steinfeld%2CI&author=Kleivi%2CK&author=Leivonen%2CSK&author=Aure%2CMR&author=Russnes%2CHG generate monthly?
- Learn how profitable https://doi.org/10.1158%2F0008-5472.CAN-11-0489 is on a monthly basis
- How much does http://scholar.google.com/scholar_lookup?&title=microRNA-associated%20progression%20pathways%20and%20potential%20therapeutic%20targets%20identified%20by%20integrated%20mRNA%20and%20microRNA%20expression%20profiling%20in%20breast%20cancer&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-11-0489&volume=71&pages=5635-5645&publication_year=2011&author=Buffa%2CFM&author=Camps%2CC&author=Winchester%2CL&author=Snell%2CCE&author=Gee%2CHE&author=Sheldon%2CH net monthly?
- Earnings of https://doi.org/10.1016%2Fj.ccr.2004.05.015
- Revenue of http://scholar.google.com/scholar_lookup?&title=A%20two-gene%20expression%20ratio%20predicts%20clinical%20outcome%20in%20breast%20cancer%20patients%20treated%20with%20tamoxifen&journal=Cancer%20Cell&doi=10.1016%2Fj.ccr.2004.05.015&volume=5&pages=607-616&publication_year=2004&author=Ma%2CXJ&author=Wang%2CZ&author=Ryan%2CPD&author=Isakoff%2CSJ&author=Barmettler%2CA&author=Fuller%2CA
- Explore the financials of https://link.springer.com/doi/10.1186/bcr1325
- What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=Gene%20expression%20profiling%20spares%20early%20breast%20cancer%20patients%20from%20adjuvant%20therapy%3A%20derived%20and%20validated%20in%20two%20population-based%20cohorts&journal=Breast%20Cancer%20Res&doi=10.1186%2Fbcr1325&volume=7&pages=R953-R964&publication_year=2005&author=Pawitan%2CY&author=Bjohle%2CJ&author=Amler%2CL&author=Borg%2CAL&author=Egyhazi%2CS&author=Hall%2CP?
- How much does https://citation-needed.springer.com/v2/references/10.1038/onc.2012.128?format=refman&flavour=references pull in?
- What's the profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=A%20Ward?
- What's the income generated by https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22A%20Ward%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en each month?
- What's the monthly money flow for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=A%20Balwierz?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22A%20Balwierz%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en gross monthly?
- How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=J%20D%20Zhang bring in?
- How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22J%20D%20Zhang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in?
- Financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=M%20K%C3%BCblbeck
- Monthly income for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22M%20K%C3%BCblbeck%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- What are the total earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Y%20Pawitan?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Y%20Pawitan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en gross monthly?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=T%20Hielscher bring in each month?
- See how much https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22T%20Hielscher%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en makes per month
- Check the income stats for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=S%20Wiemann
- How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22S%20Wiemann%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
- How much cash flow does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=%C3%96%20Sahin have monthly?
- Get to know https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22%C3%96%20Sahin%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's earnings
- How much money does https://static-content.springer.com/esm/art%3A10.1038%2Fonc.2012.128/MediaObjects/41388_2013_BFonc2012128_MOESM13_ESM.doc make?
- How much does https://s100.copyright.com/AppDispatchServlet?title=Re-expression%20of%20microRNA-375%20reverses%20both%20tamoxifen%20resistance%20and%20accompanying%20EMT-like%20properties%20in%20breast%20cancer&author=A%20Ward%20et%20al&contentID=10.1038%2Fonc.2012.128©right=The%20Author%28s%29&publication=0950-9232&publicationDate=2012-04-16&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY-NC-ND bring in each month?
- How much cash flow does https://citation-needed.springer.com/v2/references/10.1038/onc.2012.128?format=refman&flavour=citation have monthly?
- How much money does https://doi.org/10.1007/s12094-023-03189-3 make?
- How much does https://doi.org/10.1007/s11033-022-07553-4 net monthly?
- See how much https://doi.org/10.1007/s00428-021-03238-8 makes per month
- How much money does https://doi.org/10.1038/s41389-021-00309-y make?
- How much does https://doi.org/10.1007/s00109-021-02136-5 gross monthly?
- How much does https://www.protocols.io/ earn?
- What's the monthly money flow for https://www.natureindex.com/?
- How profitable is http://www.naturechina.com?
- Get to know what's the income of https://www.natureasia.com/ja-jp
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Prism.js
- Zoom.js
Emails and Hosting {✉️}
Mail Servers:
- mxa-002c5801.gslb.pphosted.com
- mxb-002c5801.gslb.pphosted.com
Name Servers:
- pdns1.ultradns.net
- pdns2.ultradns.net
- pdns3.ultradns.org
- pdns4.ultradns.org
- pdns5.ultradns.info
- pdns6.ultradns.co.uk
CDN Services {📦}
- Crossref